TY - JOUR
T1 - Therapeutic antibodies by phage display
AU - Shim, Hyunbo
N1 - Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant for Medicinal Bioconvergence Research Center (NRF-2013M3A6A4044991) and the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP (NRF-2015M3A9B6029138).
Publisher Copyright:
© 2016 Bentham Science Publishers.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: Antibody phage display is a major technological platform for the generation of fully human antibodies for therapeutic purposes. The in vitro binder selection by phage display allows researchers to have more extensive control over binding parameters and facilitates the isolation of clinical candidate antibodies with desired binding and/or functional profiles. Methods: Since the invention of antibody phage display in late 1980s, significant technological advancements in the design, construction, and selection of the antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages. Results: In this review, the background and details of antibody phage display technology, and representative antibody libraries with natural or synthetic sequence diversity and different construction strategies are described. The generation, optimization, functional and biophysical properties, and preclinical and clinical developments of some of the phage display-derived therapeutic antibodies approved for use in patients or in late-stage clinical trials are also discussed. Conclusion: With evolving novel disease targets and therapeutic strategies, antibody phage display is expected to continue to play a central role in the development of the next generation of therapeutic antibodies.
AB - Background: Antibody phage display is a major technological platform for the generation of fully human antibodies for therapeutic purposes. The in vitro binder selection by phage display allows researchers to have more extensive control over binding parameters and facilitates the isolation of clinical candidate antibodies with desired binding and/or functional profiles. Methods: Since the invention of antibody phage display in late 1980s, significant technological advancements in the design, construction, and selection of the antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages. Results: In this review, the background and details of antibody phage display technology, and representative antibody libraries with natural or synthetic sequence diversity and different construction strategies are described. The generation, optimization, functional and biophysical properties, and preclinical and clinical developments of some of the phage display-derived therapeutic antibodies approved for use in patients or in late-stage clinical trials are also discussed. Conclusion: With evolving novel disease targets and therapeutic strategies, antibody phage display is expected to continue to play a central role in the development of the next generation of therapeutic antibodies.
KW - Antibodies
KW - Antibody libraries
KW - Fully human antibodies
KW - Natural antibody libraries
KW - Phage display
KW - Semi-synthetic antibody libraries
KW - Synthetic antibody libraries
KW - Therapeutic antibodies
UR - http://www.scopus.com/inward/record.url?scp=85011044696&partnerID=8YFLogxK
U2 - 10.2174/1381612822666160923113714
DO - 10.2174/1381612822666160923113714
M3 - Review article
C2 - 27669967
AN - SCOPUS:85011044696
SN - 1381-6128
VL - 22
SP - 6538
EP - 6559
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 43
ER -